摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-[3-(2-fluorophenyl)propyl]-2-pyridin-4-yl-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one

中文名称
——
中文别名
——
英文名称
9-[3-(2-fluorophenyl)propyl]-2-pyridin-4-yl-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one
英文别名
——
9-[3-(2-fluorophenyl)propyl]-2-pyridin-4-yl-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one化学式
CAS
——
化学式
C21H21FN4O
mdl
——
分子量
364.4
InChiKey
VHNDIPHFSMWLIV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    27
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    48.8
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
    申请人:SANOFI-SYNTHELABO
    公开号:EP1184383A1
    公开(公告)日:2002-03-06
    The invention relates to a 6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents hydrogen atoms, a sulphur atom or an oxygen atom; Y represents a bond, a double bond, a triple bond, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted by a C1-6 alkyl group, a phenyl or a benzyl group; or a methylene group optionally substituted by one or two substituents; R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group or a halogen atom; when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represents a C1-6 alkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a C3-6 cycloalkyl group, a naphthyl group, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; the benzyl group, the phenyls, the naphthyl or the rings being optionally substituted by 1 to 3 substituents; when Y represents a double bond, a triple bond, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a naphthyl group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring, the benzyl group or the phenyls, the naphthyl or the rings being optionally substituted by 1 to 3 substituents ; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β.
    该发明涉及一种由式(I)表示的6,7,8,9-四氢嘧啶[1,2-a]嘧啶酮衍生物或其盐:其中:X代表氢原子、硫原子或氧原子;Y代表键、双键、三键、氧原子、硫原子、磺酰基、磺氧基、羰基、氮原子,氮原子可以选择性地被C1-6烷基、苯基或苄基取代,或者一个或两个取代基取代的亚甲基基团;R1代表2,3或4-吡啶基,可以选择性地被C1-4烷基、C1-4烷氧基或卤原子取代;当Y代表键、可以选择性取代的亚甲基基团或羰基时,R2代表C1-6烷基、C1-4烷硫基、C1-4烷氧基、C3-6环烷基、萘基、苯硫基、苄基、苯环、吡啶环、吲哚环、吡咯环、噻吩环、呋喃环或咪唑环;苄基、苯基、萘基或环可以选择性地被1至3个取代基取代;当Y代表双键、三键、氧原子、硫原子、磺酰基、磺氧基或可以选择性取代的氮原子时,R2代表C1-6烷基、C3-6环烷基、萘基、苄基、苯环、吡啶环、吲哚环、吡咯环、噻吩环、呋喃环或咪唑环,苄基或苯基、萘基或环可以选择性地被1至3个取代基取代;n代表0至3。该发明还涉及一种药物,包括所述衍生物或其盐,作为用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病的活性成分。
  • 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives
    申请人:——
    公开号:US20040087598A1
    公开(公告)日:2004-05-06
    The invention relates to pyrimidone derivative represented by formula (I) or a salt thereof wherein X represents hydrogen atoms, a sulfur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group, a 1,2-cyclopropylene, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; R1 represent a 2,3 or 4-pyridyl group optionally substituted by a C 3-6 cycloalkyl group a C 1-4 alkyl group, a C 1-4 alkoxy group, a benzyl group or a halogen atom; when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represent a C 1-16 alkyl group, a C 3-6 cycloalkyl group, a C 1-4 alkylthio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3&bgr; such as Alzheimer's disease.
    本发明涉及一种以式(I)表示的嘧啶酮衍生物或其盐,其中X代表氢原子、硫原子、氧原子或C1-2烷基和氢原子;Y代表键,乙烯基,乙炔基,1,2-环丙烷基,氧原子,硫原子,磺酰基,磺酸氧化物基,羰基,氮原子(可选择性取代)或取代的亚甲基基团;R1代表2,3或4-吡啶基团,可选择性取代为C3-6环烷基,C1-4烷基,C1-4烷氧基,苄基或卤原子;当Y代表键,可选择性取代的亚甲基基团或羰基时,则R2代表C1-16烷基,C3-6环烷基,C1-4烷硫基,C1-4烷氧基,C1-2全氟烷基,C1-3卤代烷基,5,6,7,8-四氢萘基环,萘基环,苯硫基,苄基,苯基环,吡啶基环,吲哚基环,吡咯基环,噻吩基环,呋喃基环或咪唑基环;当Y代表乙烯基,乙炔基,氧原子,硫原子,磺酰基,磺酸氧化物基或可选择性取代的氮原子时,则R2代表C1-6烷基,C3-6环烷基,C1-2全氟烷基,C1-3卤代烷基,萘基环,5,6,7,8-四氢萘基环,苄基,苯基环,吡啶基环,吲哚基环,吡咯基环,噻吩基环,呋喃基环或咪唑基环。本发明还涉及一种药物,其包含所述衍生物或其盐作为活性成分,用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病,例如阿尔茨海默病。
  • 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives
    申请人:Almario Garcia Antonio
    公开号:US20060014762A1
    公开(公告)日:2006-01-19
    The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents hydrogen atoms, a sulphur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group, a 1,2-cyclopropylene, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C 3-6 cycloalkyl group a C 1-4 alkyl group, a C 1-4 alkoxy group, a benzyl group or a halogen atom; when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-4 alkylthio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β such as Alzheimer's disease.
    本发明涉及一种由式(I)或其盐所表示的嘧啶酮衍生物:其中:X代表氢原子,硫原子,氧原子或C1-2烷基和氢原子;Y代表键,乙烯基,乙炔基,1,2-环丙基,氧原子,硫原子,磺酰基,磺酸氧基,羰基,氮原子(可选地被取代)或取代的亚甲基基团;R1代表2、3或4-吡啶基团,可选地被C3-6环烷基,C1-4烷基,C1-4烷氧基,苄基或卤原子取代;当Y代表键,可选地被取代的亚甲基基团或羰基时,R2代表C1-6烷基,C3-6环烷基,C1-4烷硫基,C1-4烷氧基,C1-2全卤代烷基,C1-3卤代烷基,5,6,7,8-四氢萘基环,萘基环,苯基硫基,苄基,苯基环,吡啶基环,吲哚基环,吡咯基环,噻吩基环,呋喃基环或咪唑基环;当Y代表乙烯基,乙炔基,氧原子,硫原子,磺酰基,磺酸氧基或可选地被取代的氮原子时,R2代表C1-6烷基,C3-6环烷基,C1-2全卤代烷基,C1-3卤代烷基,萘基环,5,6,7,8-四氢萘基环,苄基,苯基环,吡啶基环,吲哚基环,吡咯基环,噻吩基环,呋喃基环或咪唑基环。本发明还涉及一种药物,其包含所述衍生物或其盐作为活性成分,用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病,如阿尔茨海默病。
  • 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES
    申请人:ALMARIO GARCIA Antonio
    公开号:US20080027078A1
    公开(公告)日:2008-01-31
    The invention relates to therapeutic uses of a pyrimidone derivative represented by formula (I) or a salt thereof: Wherein X, Y, R1, R2, m and n are as defined herein. Specifically, a medicament comprising the said derivative or a salt thereof as an active ingredient is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β such as Alzheimer's disease.
    本发明涉及一种嘧啶酮衍生物或其盐的治疗用途,其化学式为(I),其中X、Y、R1、R2、m和n如本文所定义。具体而言,该衍生物或其盐作为活性成分的药物可用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病,例如阿尔茨海默病。
  • 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES
    申请人:SANOFI-SYNTHELABO
    公开号:EP1315731A1
    公开(公告)日:2003-06-04
查看更多

同类化合物

(N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷 顺,顺-丙二腈 非那唑啉 靛酚钠盐 靛酚 霜霉威盐酸盐 霜脲氰